natgillin/translations-raw huggingface dataset:
The observed values of the peak concentrations are 9-fold greater than the IC50 of abacavir of 0.08 µg/ml or 0.26 µM when abacavir is given at 600 mg twice daily. 
abakavira od 0,08 µg/ml ili 0,26 µM nakon primjene doze abakavira od 600 mg dvaput na dan.
While the total dolutegravir concentration in plasma was similar, a 1.5 to 2-fold increase in unbound exposure to dolutegravir was observed in subjects with moderate hepatic impairment compared to healthy controls. 
Iako je ukupna koncentracija dolutegravira u plazmi bila podjednaka, u ispitanika s umjerenim oštećenjem jetre izloženost nevezanom dolutegraviru bila
The pharmacokinetics of dolutegravir in 10 antiretroviral treatment-experienced HIV-1 infected adolescents (12 to 17 years) showed that dolutegravir 50 mg once daily dosage resulted in dolutegravir exposure comparable to that observed in adults who received dolutegravir 50 mg once daily. 
koji su prethodno liječeni antiretroviroticima, pokazala je da primjena dolutegravira u dozi od 50 mg jedanput na dan dovodi do izloženosti dolutegraviru usporedive s onom primijećenom u odraslih bolesnika koji su primali dolutegravir u dozi od 50 mg jedanput na dan.
Abacavir is primarily metabolised by the liver. 
Abakavir se prvenstveno metabolizira u jetri.
• if you have ever had liver disease, including hepatitis B or C (if you have hepatitis B infection, don't stop Triumeq without your doctor's advice, as your hepatitis may come back) 
• ako imate umjerenu ili tešku bolest jetre • ako ste nekada imali bolest jetre, uključujući hepatitis B ili C (ako imate infekciju hepatitisom B,
Liver chemistry elevations consistent with immune reconstitution syndrome were observed in some hepatitis B and/or C co-infected patients at the start of dolutegravir therapy. 
U nekih bolesnika s istodobnom infekcijom hepatitisom B i/ili C, u skladu sa sindromom imunološke rekonstitucije, primijećena su povišenja biokemijskih pokazatelja jetrene funkcije na početku liječenja dolutegravirom.
Since the recommended dose of dolutegravir is 50 mg twice daily when co-administered with tipranavir/ritonavir, the coadministration of tipranavir/ritonavir with Triumeq is not recommended. 
Budući da preporučena doza dolutegravira pri istodobnoj primjeni s tipranavirom/ritonavirom iznosi 50 mg dvaput na dan, ne preporučuje se istodobna primjena tipranavira/ritonavira i lijeka Triumeq.
Hypersensitivity reactions (see section 4.8) 
sindrom imunološke rekonstitucije (vidjeti dio 4.4)
- After stopping treatment with Triumeq for reasons of a suspected HSR, Triumeq or any other medicinal product containing abacavir or dolutegravir must never be re-initiated. 
Nakon prekida liječenja lijekom Triumeq zbog suspektne reakcije preosjetljivosti, nikada se ne smije ponovno započeti liječenje lijekom Triumeq niti bilo kojim drugim lijekom koji sadrži abakavir ili dolutegravir.
Early Switch ABC/DTG/3TC FDC N=275 n (%) 
Rani prelazak na fiksnu kombinaciju ABC/DTG/3TC N=275 n (%)
In 100% human serum, the mean fold shift for dolutegravir activity was 75-fold, resulting in protein adjusted IC90 of 0.064 ug/mL. 
puta, što je za posljedicu imalo vrijednost IC90 prilagođenu za proteine od 0,064 μg/ml.
• numbness, tingly feelings in the skin (pins and needles) 
• utrnulost, trnci na koži (mravinjanje)
Since the recommended dose of dolutegravir is 50 mg twice daily when co-administered with carbamazepine, DTG/ABC/3TC FDC is not recommended for patients taking carbamazepine. 
S obzirom da je preporučena doza dolutegravira 50 mg dvaput na dan kad se istodobno primjenjuje s karbamazepinom, fiksna kombinacija dolutegravir/abakavir/lamivudin se ne preporučuje u bolesnika koji uzimaju karbamazepin.
- Triumeq should never be initiated in patients with a positive HLA-B*5701 status, nor in patients with a negative HLA-B*5701 status who had a suspected abacavir HSR on a previous abacavircontaining regimen. 
statusom, niti u bolesnika s negativnim HLA-B*5701 statusom za koje se sumnja da su imali reakciju preosjetljivosti na abakavir tijekom prethodnog liječenja režimom koji je sadržavao abakavir.
The apparent volume of distribution of dolutegravir (following oral administration of suspension formulation, Vd/F) is estimated at 12.5 L. Intravenous studies with abacavir and lamivudine showed that the mean apparent volume of distribution is 0.8 and 1.3 l/kg respectively. 
U ispitivanjima intravenske primjene abakavira i lamivudina utvrđeno je da srednja vrijednost prividnog volumena distribucije iznosi 0,8 l/kg odnosno 1,3 l/kg.
Virologically suppressed (HIV-1 RNA <50 c/mL) subjects were randomly assigned (1:1) to continue their current ART regimen (2 NRTIs plus either a PI, NNRTI, or INI), or switch to ABC/DTG/3TC FDC once daily (Early Switch). 
Ispitanici s virusnom supresijom (HIV-1 RNK < 50 kopija/ml) bili su randomizirani (1:1) za nastavak dotadašnje antiretrovirusne terapije (2 NRTI-ja plus IP, NNRTI ili inhibitor integraze [INI]) ili za prelazak na fiksnu kombinaciju
Renal impairment Triumeq is not recommended for use in patients with a creatinine clearance < 50 ml/min (see section 
Ne preporučuje se primjena lijeka Triumeq u bolesnika s klirensom kreatinina < 50 ml/min (vidjeti dio 5.2).
Cmax ↑ 5% Cτ ↑ 8% Boceprevir ↔ (historical controls) 
Ostali antivirotici boceprevir dolutegravir ↔ AUC ↑ 7% Cmax ↑ 5% Cτ ↑ 8% boceprevir ↔ (kontrole iz prethodnih ispitivanja)
Since the dose of dolutegravir is 50 mg twice daily when co-administered with efavirenz, the co-administration of efavirenz with Triumeq is not recommended (see section 4.4). 
50 mg dvaput na dan, ne preporučuje se istodobna primjena efavirenza i lijeka Triumeq (vidjeti dio 4.4).
Package leaflet: Information for the patient Triumeq 50 mg/600 mg/300 mg film-coated tablets dolutegravir/abacavir/lamivudine 
Uputa o lijeku: Informacije za bolesnika Triumeq 50 mg/600 mg/300 mg filmom obložene tablete dolutegravir/abakavir/lamivudin
Baseline CD4+ (cells/ mm3) 
(stanice/mm3)
In serial passage with strain NL432-based site directed mutants at N155H or E92Q, no further selection of resistance was seen (fold change unchanged around 1). 
ili E92Q, nije primijećena daljnja selekcija rezistencije (vrijednost promjene od približno 1 ostala je nepromijenjena).
Co-administration with nevirapine may decrease dolutegravir plasma concentration due to enzyme induction and has not been studied. 
Istodobna primjena s nevirapinom nije ispitivana, ali bi zbog indukcije enzima mogla smanjiti koncentraciju dolutegravira u plazmi.
For patients co-infected with hepatitis B who are being treated with a lamivudine containing medicinal product such as Triumeq and subsequently become pregnant, consideration should be given to the possibility of a recurrence of hepatitis on discontinuation of lamivudine. 
poput lijeka Triumeq, i u međuvremenu zatrudne, mora se razmotriti mogućnost recidiva hepatitisa nakon prekida liječenja lamivudinom.
In HIV-1-infected adult subjects following dolutegravir 50 mg once daily, the steady-state pharmacokinetic parameters (geometric mean [%CV]) based on population pharmacokinetic analyses were AUC(0-24) = 53.6 (27) µg.h/mL, Cmax = 3.67 (20) µg/mL, and Cmin = 1.11 (46) µg/mL. 
AUC(0-24) = 53,6 (27) µg.h/ml, Cmax = 3,67 (20) µg/ml i Cmin = 1,11 (46) µg/ml.
You should never take abacavir or abacavircontaining products again if you have a hypersensitivity reaction: it can be life threatening. 
Ako razvijete reakciju preosjetljivosti ne smijete više nikada uzimati abakavir ili lijekove koji sadrže abakavir: to može ugroziti život.
Dolutegravir ↔ AUC ↑ 11% Cmax ↑ 7% Cτ ↑ 28% 
lopinavir+ritonavir+etravirin/ dolutegravir dolutegravir ↔ AUC ↑ 11% Cmax ↑ 7% Cτ ↑ 28%
Renal impairment Pharmacokinetic data have been obtained for dolutegravir, lamivudine and abacavir separately. 
Oštećenje bubrežne funkcije Prikupljeni su farmakokinetički podaci za dolutegravir, lamivudin i abakavir kao zasebne djelatne tvari.
There are no data available on the effects of the combination of dolutegravir, abacavir and lamivudine in animals, except a negative in vivo rat micronucleus test which tested the effects of the combination of abacavir and lamivudine. 
osim negativnog nalaza mikronukleusnog testa provedenog na štakorima in vivo, kojim su se ispitivali učinci kombinacije abakavira i lamivudina.
Joint pain, stiffness and bone problems 
Bol u zglobovima, ukočenost i tegobe s kostima
Uncommon suicidal ideation or suicide attempt (particularly in patients with a pre-existing history of depression or psychiatric illness) 
neuobičajeni snovi, depresija, anksioznost1, noćne more, poremećaj spavanja manje često suicidalne ideje ili pokušaj suicida (osobito u bolesnika s depresijom ili psihijatrijskom bolesti u anamnezi)
Since the dose of dolutegravir is 50 mg twice daily when coadministered with nevirapine, the coadministration of nevirapine with Triumeq is not recommended. 
Budući da doza dolutegravira pri istodobnoj primjeni s nevirapinom iznosi 50 mg dvaput na dan, ne preporučuje se istodobna primjena nevirapina i lijeka Triumeq.
hypertriglyceridaemia, hyperglycaemia 
manje često hipertrigliceridemija, hiperglikemija vrlo rijetko laktacidoza1
→ Talk to your doctor for further advice on taking antacid medicines with Triumeq. 
Obratite se svom liječniku za dodatne savjete o uzimanju lijekova koji smanjuju količinu kiseline u želucu zajedno s lijekom Triumeq.
Since the dose of dolutegravir is 50 mg twice daily when co-administered with rifampicin, the co-administration of rifampicin with Triumeq is not recommended. 
Budući da doza dolutegravira pri istodobnoj primjeni s rifampicinom iznosi 50 mg dvaput na dan, ne preporučuje se istodobna primjena rifampicina i lijeka Triumeq.
Treatment with Triumeq must be stopped without delay if HSR cannot be ruled out on clinical grounds, and therapy with Triumeq or other abacavir or dolutegravir containing products must never be re-initiated. 
Ako se klinički ne može isključiti reakcija preosjetljivosti, primjena lijeka Triumeq mora se bez odlaganja obustaviti te se više nikada ne smije ponovno započeti liječenje lijekom Triumeq ili drugim lijekovima koji sadrže abakavir ili dolutegravir.
AUC ↔ Cmax ↓35% Methadone: CL/F ↑22% 
metadon: CL/F ↑22%
Diagnosis of Abacavir Hypersensitivity Reaction Major symptoms associated with ABC HSR are fever (~80%), rash (~70%), gastrointestinal symptoms (>50%) such as nausea, abdominal pain, vomiting, and diarrhoea, generalise malaise, fatigue, and headache (~50%) and other symptoms (~30%) such as respiratory, mucosal, and musculoskeletal symptoms. 
opće malaksalosti, umor i glavobolja (~50%) te drugi simptomi (~30%), poput respiratornih simptoma, simptoma na sluznicama i mišićno-koštanih simptoma.
Film-coated tablet (tablet) 
Jedna filmom obložena tableta sadrži:
Dolutegravir ↓ AUC ↓ 57% Cmax ↓ 39% Cτ ↓ 75% 
efavirenz/dolutegravir dolutegravir ↓ AUC ↓ 57% Cmax ↓ 39% Cτ ↓ 75%
Table 7: Outcomes of randomized treatment of STRIIVING (snapshot algorithm) Study Outcomes (Plasma HIV-1 RNA <50 c/mL) at Week 24 and Week 48 - Snapshot Analysis (ITT-E Population) 
Ishodi ispitivanja (plazmatski HIV-1 RNK < 50 kopija/ml) u 24. tjednu i 48. tjednu - analiza podataka prikupljenih pri samo jednom posjetu (engl. snapshot analysis) (ITT-E populacija) Fiksna kombinacija ABC/DTG/3TC N=275 n (%)
Since the recommended dose of dolutegravir is 50 mg twice daily when co-administered with these metabolic inducers, DTG/ABC/3TC FDC is not recommended for patients taking these metabolic inducers. 
S obzirom da je preporučena doza dolutegravira 50 mg dvaput na dan kad se istodobno primjenjuje s navedenim metaboličkim induktorima, fiksna kombinacija dolutegravir/abakavir/lamivudin se ne preporučuje u bolesnika koji uzimaju navedene metaboličke induktore.
Oral administration of dolutegravir to pregnant rats at doses up to 1000 mg/kg daily from days 6 to 17 of gestation did not elicit maternal toxicity, developmental toxicity or teratogenicity (50 times the 50 mg human clinical exposure when administered in combination with abacavir and lamivudine based on AUC). 
6. do 17. dana gestacije nije uzrokovala toksičnost za majku, razvojnu toksičnost niti teratogenost (izloženost 50 puta veća od kliničke izloženosti u ljudi pri primjeni doze od 50 mg u kombinaciji s abakavirom i lamivudinom, što je utvrđeno na temelju AUC-a).
NAME OF THE MEDICINAL PRODUCT Triumeq 50 mg/600 mg/300 mg tablets dolutegravir/abacavir/lamivudine 
Triumeq 50 mg/600 mg/300 mg tablete dolutegravir/abakavir/lamivudin
Rare side effects that may show up in blood tests are: • increase in an enzyme called amylase 
• povećanje razine enzima koji se zove amilaza
Each tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir, 600 mg abacavir (as sulfate) and 300 mg lamivudine. 
Jedna tableta sadrži 50 mg dolutegravira u obliku dolutegravirnatrija, 600 mg abakavira (u obliku abakavirsulfata) i 300 mg lamivudina.
Patients should be advised that Triumeq or any other antiretroviral therapy does not cure HIV infection and that they may still develop opportunistic infections and other complications of HIV infection. 
Bolesnike se mora upozoriti da Triumeq ili bilo koja druga antiretrovirusna terapija ne može izliječiti
Dolutegravir ↓ AUC ↓ 22% Cmax ↓ 11% Cτ ↓ 38% 
darunavir+ritonavir/ dolutegravir dolutegravir ↓ AUC ↓ 22% Cmax ↓ 11% Cτ ↓ 38%
2) you get one or more symptoms from at least TWO of the following groups - fever - shortness of breath, sore throat or cough - nausea or vomiting or diarrhoea or abdominal pain - severe tiredness or achiness or generally feeling ill 
- nedostatak zraka, grlobolja ili kašalj - mučnina ili povraćanje ili proljev ili bol u trbuhu - izrazit umor ili bolovi ili opće loše osjećanje
headache 
Nuspojava
Dolutegravir↓ AUC ↓ 35% Cmax ↓ 24% Cτ ↓ 49% 
fosamprenavir+ritonavir/ dolutegravir dolutegravir↓ AUC ↓ 35% Cmax ↓ 24% Cτ ↓ 49%
The apparent oral clearance (CL/F) is approximately 1 L/hr in HIV-infected patients based on a population pharmacokinetic analysis. 
Na temelju populacijske farmakokinetičke analize, prividni klirens nakon peroralne primjene (CL/F) u bolesnika s HIV infekcijom iznosi približno 1 l/h.
Very common side effects These may affect more than 1 in 10 people: 
Vrlo rijetke nuspojave Mogu se javiti u do 1 na 10 000 osoba:
Frequency 
Razno
Hepatic impairment Pharmacokinetic data has been obtained for dolutegravir, abacavir and lamivudine separately. 
Oštećenje jetrene funkcije Prikupljeni su farmakokinetički podaci za dolutegravir, abakavir i lamivudin kao zasebne djelatne tvari.
Oral administration of dolutegravir to pregnant rabbits at doses up to 1000 mg/kg daily from days 6 to 18 of gestation did not elicit developmental toxicity or teratogenicity (0.74 times the 50mg human clinical exposure when administered in combination with abacavir and lamivudine based on AUC). 
6. do 18. dana gestacije nije uzrokovala razvojnu toksičnost niti teratogenost (izloženost 0,74 puta veća od kliničke izloženosti u ljudi pri primjeni doze od 50 mg u kombinaciji s abakavirom i lamivudinom, što je utvrđeno na temelju AUC-a).
Monitoring of liver chemistries is recommended in patients with hepatitis B and/or C co-infection. 
U bolesnika s istodobnom infekcijom hepatitisom B i/ili C preporučuje se praćenje biokemijskih pokazatelja jetrene funkcije. (Vidjeti dio 'Bolesnici s kroničnim hepatitisom B ili C'
In vitro, lamivudine did not inhibit or induce CYP enzymes (such as CYP3A4, CYP2C9 or CYP2D6) and demonstrated no or weak inhibition of OATP1B1, OAT1B3, OCT3, BCRP, P-gp, MATE1 or MATE2-K. Lamivudine is therefore not expected to affect the plasma concentrations of drugs that are substrates of these enzymes or transporters. 
In vitro, lamivudin nije inhibirao ni inducirao CYP enzime (kao što su CYP3A4, CYP2C9 ili CYP2D6) te nije inhibirao ili je slabo inhibirao OATP1B1, OAT1B3, OCT3, BCRP, P-gp, MATE1 ili MATE2-K.
Dolutegravir ↔ AUC ↑ 11% Cmax ↑ 6% 
Kortikosteroidi prednizon dolutegravir ↔ AUC ↑ 11% Cmax ↑ 6% Cτ ↑ 17%
Discontinued study/study drug for other reasons§ Missing data during window but on study 
Prekid sudjelovanja u ispitivanju/primjene ispitivanog lijeka zbog nuspojave ili smrti‡ Prekid sudjelovanja u ispitivanju/primjene ispitivanog lijeka zbog drugih razloga§ Nema podataka za promatrano razdoblje, ali bolesnik sudjeluje u ispitivanju
In vivo, dolutegravir did not have an effect on midazolam, a CYP3A4 probe. 
Učinak dolutegravira, abakavira i lamivudina na farmakokinetiku drugih lijekova In vivo dolutegravir nije utjecao na midazolam, probni supstrat za CYP3A4.
Table 5: Demographics and Week 48 virologic outcomes of randomized treatment of FLAMINGO (snapshot algorithm) 
Tablica 5: Demografske značajke i virološki ishodi u 48. tjednu randomiziranog liječenja u ispitivanju
Dolutegravir ↔ AUC ↑ 1% Cmax ↓ 3% Cτ ↓ 8% Tenofovir ↔ 
Nukleozidni inhibitori reverzne transkriptaze (NRTI) tenofovir emtricitabin, didanozin, stavudin, zidovudin dolutegravir ↔ AUC ↑ 1% Cmax ↓ 3% Cτ ↓ 8% tenofovir ↔
The adjusted difference in proportion and 95% CI [ABC/DTG/3TC vs current ART] were 3.4%; 95% CI: [-9.1, 2.4]. 
naspram dotadašnje antiretrovirusne terapije) iznosili su 3,4% odnosno 95% CI: (-9,1; 2,4).
asthenia, fever1, malaise1 
astenija, vrućica1, malaksalost1
Dolutegravir hypersensitivity 
Preosjetljivost na dolutegravir
Dolutegravir ↓ AUC ↓ 59% Cmax ↓ 47% Cτ ↓ 76% 
tipranavir+ritonavir/ dolutegravir dolutegravir ↓ AUC ↓ 59% Cmax ↓ 47% Cτ ↓ 76%
Investigations: Common: 
umor često:
NAME OF THE MEDICINAL PRODUCT Triumeq 50 mg/600 mg/300 mg film-coated tablets dolutegravir/abacavir/lamivudine 
Triumeq 50 mg/600 mg/300 mg filmom obložene tablete dolutegravir/abakavir/lamivudin
Psychiatric disorders: 
Psihijatrijski poremećaji: vrlo često:
Dolutegravir ↓ AUC ↓ 49% Cmax ↓ 33% Cτ ↓ 73% 
Antikonvulzivi karbamazepin/dolutegravir dolutegravir ↓ AUC ↓ 49% Cmax ↓ 33% Cτ ↓ 73%
Missing data during window but on study 
Nema podataka za promatrano razdoblje, ali bolesnik sudjeluje u ispitivanju
Darunavir ↔ Ritonavir ↔ (induction of UGT1A1 and CYP3A enzymes) 
darunavir ↔ ritonavir ↔ (indukcija enzima UGT1A1 i CYP3A)
Vistor hf. 
Probir na HLA
Management of ABC HSR reaction 
Zbrinjavanje reakcije preosjetljivosti na abakavir
In the primary 48 weeks analysis, the proportion of patients with virologic suppression in the dolutegravir + ABC/3TC arm, was superior to the EFV/TDF/FTC arm, p=0.003, the same treatment difference was observed in subjects defined by baseline HIV RNA level (< or > 100,000 copies/mL). 
U primarnoj analizi 48 tjedana liječenja, udio bolesnika s virološkom supresijom u skupini liječenoj kombinacijom dolutegravir + ABC/3TC bio je superioran u odnosu na skupinu koja je primala
Discontinued study/study drug due to adverse event or death‡ 
Prekid sudjelovanja u ispitivanju/primjene ispitivanog lijeka zbog nuspojave ili smrti‡ Prekid sudjelovanja u ispitivanju/primjene ispitivanog lijeka zbog drugih razloga§
What Triumeq looks like and contents of the pack Triumeq film-coated tablets are purple, biconvex, oval tablets, debossed with “572 Trı” on one side. 
Triumeq filmom obložene tablete su ljubičaste, bikonveksne, ovalne tablete s utisnutom oznakom
Very rare side effects that may show up in blood tests are: • a failure of the bone marrow to produce new red blood cells (pure red cell aplasia). 
• nemogućnost koštane srži da proizvede nove crvene krvne stanice (izolirana aplazija crvenih krvnih stanica) Ako primijetite bilo koju nuspojavu
What Triumeq contains - The active substances are dolutegravir, abacavir and lamivudine. 
- Djelatne tvari su dolutegravir, abakavir i lamivudin.
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 50 mg dolutegravir (as sodium), 600 mg abacavir (as sulfate), 300 mg lamivudine. 
Jedna filmom obložena tableta sadrži 50 mg dolutegravira (u obliku dolutegravirnatrija), 600 mg abakavira (u obliku abakavirsulfata) i 300 mg lamivudina.
Virologic Success Virologic Failure Reasons Data in window not below threshold No Virologic Data Discontinued due to AE or death Discontinued for other reasons Missing data during window but on study ABC/DTG/3TC FDC = abacavir/dolutegravir/lamivudine fixed-dose combination; AE = adverse event; ART = antiretroviral therapy; HIV-1 = human immunodeficiency virus type 1; ITT-E = intent-to-treat exposed; W = week. 
ABC/DTG/3TC = abakavir/dolutegravir/lamivudin; HIV-1 = virus humane imunodeficijencije tipa 1; ITT-E (intent-to-treat exposed) = populacija predviđena za liječenje izložena lijeku.
Since the recommended dose of dolutegravir is 50 mg twice daily when co-administered with St. John's wort, DTG/ABC/3TC FDC is not recommended. 
S obzirom da je preporučena doza dolutegravira 50 mg dvaput na dan kad se primjenjuje istodobno s gospinom travom, fiksna kombinacija dolutegravir/abakavir/lamivudin se ne preporučuje.
Hepatic impairment 
• otežanim disanjem
Hypersensitivity reactions 
Klinički opis reakcija preosjetljivosti
Dolutegravir↓ (Not studied, decrease expected due to induction of UGT1A1 and CYP3A enzymes, a similar reduction in exposure as observed with carbamazepine is 
Biljni lijekovi gospina trava/dolutegravir dolutegravir↓ (nije ispitivano, očekuje se smanjenje koncentracije zbog indukcije enzima UGT1A1 i CYP3A,
De novo resistance in patients failing therapy in SINGLE, SPRING-2 and FLAMINGO 
De novo rezistencija u bolesnika s neuspješnim odgovorom na liječenje u ispitivanjima SINGLE,
Virologic Outcomes of Randomized Treatment of SINGLE at 48 Weeks (Snapshot algorithm) 
Tablica 3: Virološki ishodi randomiziranog liječenja u ispitivanju SINGLE nakon 48 tjedana
Abacavir 
triumeq
Antidiabetics Metformin/Dolutegravir 
Hematološki simptomi limfopenija
Effect of dolutegravir: NGMN ↔ AUC ↓ 2% Cmax ↓ 11% 
NGMN ↔ AUC ↓ 2% Cmax ↓ 11%
• muscle pain and discomfort 
• bol i nelagoda u mišićima
Dolutegravir 
Učinci dolutegravira:
Metformin ↑ Dolutegravir ↔ When co-administered with dolutegravir 50mg QD: 
Antidijabetici metformin/dolutegravir metformin ↑ dolutegravir ↔ Kad se istodobno primjenjuje s dolutegravirom 50 mg jedanput na dan: metformin
Do not take an antacid during the 6 hours before you take Triumeq, or for at least 2 hours after you take it. Other acid-lowering medicines like ranitidine and omeprazole can be taken at the same time as Triumeq. 
Ne smijete uzeti antacid unutar 6 sati prije primjene lijeka Triumeq niti još najmanje 2 sata nakon njegove primjene.
If you have stopped taking Triumeq because of a hypersensitivity reaction, you must NEVER AGAIN take Triumeq, or any other medicine containing abacavir. 
Ako ste prestali uzimati Triumeq zbog reakcije preosjetljivosti, NIKADA VIŠE ne smijete uzeti
Dolutegravir ↓ AUC ↓ 33% Cmax ↓ 35% C24 ↓ 32% 
multivitaminski pripravci (koji sadrže kalcij, željezo i magnezij)/dolutegravir dolutegravir ↓ AUC ↓ 33% Cmax ↓ 35% C24 ↓ 32%
Virologic Failure Reasons Data in window not below 50 c/mL threshold Discontinued for lack of efficacy Discontinued for other reason while not below threshold No Virologic Data 
Prekid liječenja zbog drugih razloga dok razina nije bila ispod granične vrijednosti
Contact your doctor immediately: 1 if you get a skin rash, OR 2 if you get symptoms from at least 2 of the following groups: fever shortness of breath, sore throat or cough nausea or vomiting, diarrhoea or abdominal pain severe tiredness or aches and pains, or generally feeling ill. 
vrućica nedostatak zraka, grlobolja ili kašalj mučnina ili povraćanje ili proljev ili bol u trbuhu izrazit umor ili tupi bolovi i probadanje ili opće loše osjećanje Liječnik će Vam možda savjetovati da prestanete uzimati Triumeq.
AUC ↓ 25% Cmax ↓ 12% Cτ ↓ 36% 
darunavir+ritonavir+etravirin/ dolutegravir dolutegravir ↓ AUC ↓ 25% Cmax ↓ 12% Cτ ↓ 36%
Female 
OBLIK
• stomach ache 
• glavobolja • proljev
• headache 
• glavoboljom
Dolutegravir ↔ AUC ↓ 4% Cmax ↔ 0% C24 ↓ 6% 
lopinavir+ritonavir/ dolutegravir lopinavir+ritonavir/ abakavir dolutegravir ↔ AUC ↓ 4% Cmax ↔ 0% C24↔↓ 6%
No recommendation on dose reduction is possible in patients with mild hepatic impairment due to substantial variability of abacavir exposure. 
Zbog znatne varijabilnosti u izloženosti abakaviru, ne može se dati preporuka za smanjenje doze u bolesnika s blagim oštećenjem jetrene funkcije.